A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
about
Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitroInhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.
P2860
A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@ast
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@en
type
label
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@ast
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@en
prefLabel
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@ast
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@en
P2860
P356
P1476
A novel derivative of doxorubi ...... nd osteosarcoma cells in vitro
@en
P2093
Kusum Rathore
P2860
P304
P356
10.2147/DDDT.S90859
P407
P577
2015-09-25T00:00:00Z